Zum Hauptinhalt springen

Hepatitiden

26. November 2020 | Hepatitiden

Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review.

Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review. Sperle I, Steffen G, Leendertz SA, Sarma N, Beermann S, Thamm R, Simeonova Y, Cornberg M, Wedemeyer H, Bremer V, Zimmermann R, Dudareva S. Front Public He...

26. November 2020 | Hepatitiden

Hepatitis C micro-elimination among people on opioid agonist therapy is a low-hanging fruit.

Hepatitis C micro-elimination among people on opioid agonist therapy is a low-hanging fruit. Bruggmann P, Maeschli B. Swiss Med Wkly. 2020 Sep 18;150:w20348. doi: 10.4414/smw.2020.20348. PMID: 33035351. https://smw.ch/article/doi/sm...

26. November 2020 | Hepatitiden

Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents.

Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents. Hong J, Wright RC, Partovi N, Yoshida EM, Hussaini T. J Clin Transl Hepatol. 2020 Sep 28;8(3):322-335. doi: 10.14218/JCT...

26. November 2020 | Hepatitiden

High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use.

High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use. Tamori A, Uchida-Kobayashi S, Kozuka R, Motoyama H, Yoshida K, Odagiri N, Kotani K, Kawamura E, Fujii H, Hagihara A, Enomot...

26. November 2020 | Hepatitiden

Optimizing Hepatitis C Virus (HCV) Treatment in a US Colocated HCV/Opioid Agonist Therapy Program.

Optimizing Hepatitis C Virus (HCV) Treatment in a US Colocated HCV/Opioid Agonist Therapy Program. Habchi J, Thomas AM, Sprecht-Walsh S, Arias E, Bratberg J, Hurley L, Hart S, Taylor LE. Open Forum Infect Dis. 2020 Oct 13;7(10):ofaa3...

26. November 2020 | Hepatitiden

Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study.

Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study. Sanvisens A, Rivas I, Faure E, Espinach N, Hernandez-Rubio A, Majó X, Colom J, Muga R. World J Gastroenterol. 2020 Oct 14;26(38):5874-...

26. November 2020 | Hepatitiden

The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.

The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Maticic, M., Pirnat, Z., Leicht, A. et al. Harm Reduct J 17, 89 (2020). https://doi.org/10.1186/s12954-020-00439...

Weitere Beiträge ansehen

Weitere
akutelle Informationen
zu den Themengebieten